Change country
Home

Goat Anti-LRRK2 / PARK8 (near C Terminus) Antibody (EB06550)

Related Products: EBP06550 - Immunizing Peptide, EBP07172 - Immunizing Peptide, Goat Anti-LRRK2 / PARK8 (internal) Antibody
Code Name Applications Availability Size Tested species Price Grade  
EB06550 Goat Anti-LRRK2 / PARK8 (near C Terminus) Antibody Pep-ELISA, IF Yes 100µg specific antibody in 200µl Human $411.00 Elite

Ordering Information for

Order direct from Everest

$73.00: Overnight shipping to United States of America
Sent via overnight courier arrives approximately next day to mainland USA. Please note that your order will be shipped by our parent company Vector Laboratories.

Order offline

99% of products are held in stock for immediate shipment, see individual product pages for availability.

Please order through the US Dollar shopping cart (links on each product page) or we accept orders by email ([email protected]) Please include the following information with your order:

  • Product code(s)
  • Purchase order number
  • Delivery and invoice address
  • Contact telephone number and email address

In stock orders received by 11 am PST on Monday through Friday are shipped the same day.

Orders are shipped by our parent company Vector Laboratories, 6737 Mowry Avenue, Newark CA 94560, USA. 
EB06550 1
EB06550 Immunofluorescence analysis of paraformaldehyde fixed A431 cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml), showing vesicle staining. The nuclear stain is DAPI (blue).
EB06550 2
Negative control: Unimmunized goat IgG (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml). EB06550 Immunofluorescence analysis of paraformaldehyde fixed A549 cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml), showing nuclear and vesicle staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml).
Click here to download PDF datasheet.

Target Protein

Principal Names: LRRK2, PARK8, ROCO2, FLJ45829, DKFZp434H2111, leucine-rich repeat kinase 2, dardarin, Parkinson disease (autosomal dominant) 8
Official Symbol: LRRK2
Accession Number(s): NP_940980.3
Human GeneID(s): 120892

Immunogen

Peptide with sequence CELAEKMRRTSV, from the internal region (near the C Terminus) of the protein sequence according to NP_940980.3.

Please note the peptide is available for sale.

Purification and Storage

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin.
Aliquot and store at -20°C. Minimize freezing and thawing.

Applications Tested

Peptide ELISA: antibody detection limit dilution 1:128000.
Western blot: Not yet tested - our routine western blotting protocol does not allow for the detection of proteins >250kDa (calculated MWt of approx. 286kDa according to NP_940980.3). However, customer testing has shown bands at >250kDa + 140kDa, which has been observed by other commercial sources of LRRK2 antibodies.

Immunofluorescence: Strong expression of the protein seen in the vesicles of A431 cells and in the vesicles and nuclei of A549 cells. Recommended concentration: 10µg/ml.

Species Reactivity

Tested: Human
Expected from sequence similarity: Human

Specific References

This antibody has been successfully used in the following paper:
Adrien De Guilhem De Lataillade, Martial Caillaud, Thibauld Oullier, Philippe Naveilhan, Carolina Pellegrini, Eduardo Tolosa, Michel Neunlist, Malvyne Rolli-Derkinderen, Ellen Gelpi, Pascal Derkinderen
LRRK2 expression in normal and pathologic human gut and in rodent enteric neural cell lines.
J Neurochem. 2023 Jan;164(2):193-209.
PMID: 36219522

This antibody (previous batch) has been successfully used in ICC on Human:
Sharma S, Bandopadhyay R, Lashley T, Renton AE, Kingsbury AE, Kumaran R, Kallis C, Vilariño-Güell C, O'Sullivan SS, Lees AJ, Revesz T, Wood NW, Holton JL.
LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: A morphological and quantitative study.
Neuropathol Appl Neurobiol. 2011 Jun 23.
PMID: 21696411

This antibody (previous batch) has been successfully used in IEM:
Alegre-Abarrategui J, Christian H, Lufino MM, Mutihac R, Venda LL, Ansorge O, Wade-Martins R.
LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model.
Hum Mol Genet. 2009 Nov 1;18(21):4022-34.
PMID: 19640926

This antibody (previous batch) has been successfully used in WB and IHC on Human:
Alegre-Abarrategui J, Ansorge O, Esiri M, Wade-Martins R.
LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease.
Neuropathol Appl Neurobiol. 2007 Oct 26.
PMID: 17971075

Product Reviews

Please login to review this product.